sur GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Presents LUMEVOQ® at NANOS 2025
GenSight Biologics, a key player in gene therapies for neurodegenerative diseases, is presenting data on its lead product, LUMEVOQ®, in Tucson at the 51st Annual NANOS Meeting. This year's focus is on Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disorder leading to rapid vision loss.
Experts will share their findings on various aspects of LUMEVOQ®, including predictors of treatment response and comparisons with other treatments such as idebenone. The conference, which takes place from March 15 to 20, 2025, will also highlight the long-term effectiveness of bilateral treatments.
It is also an opportunity to discuss real-life experiences and the impact of these advances on the daily lives of patients with this disease.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de GENSIGHT BIOLOGICS S.A.